What happens when the cutting edge of biotechnology moves faster than the regulatory frameworks designed to protect us?
In this compelling case, Kris DeVault faces a race against time for his son Brody, who developed severe developmental delays diagnosed via genetic testing. Facing limited options, families like the DeVaults look toward Montana’s expanded “Right to Try” legislation, which grants terminally or severely ill patients permission to access experimental, non-FDA-approved therapies.
From an advanced systems and tech governance perspective, this scenario mirrors the classic *Collingridge Dilemma* in technology policy: regulating early-stage innovation is difficult because outcomes are uncertain, but waiting until full data maturity can mean catastrophic delays for end-users. Here, society clashes over the *Precautionary Principle* versus dynamic, agile access to experimental bio-data and personalized therapeutics.
While bypassing traditional, multi-phase trial safety protocols offers immediate hope, it raises profound ethical questions for tech and medical infrastructure: Does decentralized access to unverified treatments jeopardize empirical safety standards and data integrity, or is strict centralized regulation an outdated bottleneck in the age of rapid genetic engineering? How should future health-tech systems balance real-time algorithmic risk assessment with fundamental human compassion?
—
當前沿生物科技的演進速度遠超監管框架的更新步伐，我們該如何在風險控制與拯救生命之間取得平衡？
本文探討了 Kris DeVault 為其幼子 Brody 尋求一線生機的艱難歷程。Brody 在基因檢測後被診斷出患有罕見的基因缺陷與嚴重發育遲緩。面對傳統療法的局限，這類家庭正寄望於蒙大拿州新通過的「試用權」（Right to Try）法案，該法允許患有重症的個體提早接觸未經完整官方審批的實驗性醫療技術。
從資訊系統與科技治理的角度來看，這完美契合了科技政策中的「科林格里奇困境」（Collingridge Dilemma）——新興技術早期的風險難以精確估算，但若等到數據完全驗證，往往已錯失最佳救治時機。這背後是傳統「預防原則」（Precautionary Principle）與現代「敏捷迭代」開發邏輯的深度碰撞。
繞過嚴格的臨床試驗流程，固然為個體提供了救命的可能，但也帶來了嚴峻的思考：在缺乏完整數據集驗證的情況下開放實驗性療法，究竟是賦權於患者，還是將系統性風險轉嫁給個體？未來的生醫資訊系統又該如何在數據安全、倫理審查與人道救助之間建立動態平衡？
#Biotech #Bioethics #RightToTry #ITProTutor
Source: MIT Technology Review